Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target

Benzinga Newsdesk www.benzinga.com Positive 79.8%

Neg 0% Neu 0% Pos 79.8%

Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.